Myeloablative Chemotherapy

Myeloablative Chemotherapy is a type of high-dose chemotherapy that completely eradicates bone marrow function, requiring subsequent hematopoietic stem cell transplantation to restore hematopoiesis.

1.3K

Publications

88.9K

Citations

8.3K

Authors

1.8K

Institutions

Publications per year

2017–2026

151

Variants

Myeloablative Therapy

Publications

1.3K

1–5 of 1.3K

Authors

8.3K

  1. HM
    Hagop M. Kantarjian

    The University of Texas MD Anderson Cancer Center, United States

    41 publications · 5.6K citations

    24

    h-index

  2. FR
    Frederick R. Appelbaum

    Fred Hutch Cancer Center, United States

    21 publications · 2K citations

    20

    h-index

  3. EH
    Elihu H. Estey

    The University of Texas MD Anderson Cancer Center, United States

    21 publications · 2.7K citations

    19

    h-index

  4. JL
    Jonathan L. Finlay

    Children's Hospital of Los Angeles, United States

    17 publications · 1.6K citations

    17

    h-index

  5. RE
    Richard E. Champlin

    The University of Texas MD Anderson Cancer Center, United States

    17 publications · 2.1K citations

    16

    h-index

1–5 of 8.3K

Venues

  1. Blood

    152 publications · 20.9K citations

    71

    h-index

  2. Journal of Clinical Oncology

    101 publications · 15.1K citations

    65

    h-index

  3. PubMed

    Repository · 166 publications · 8.4K citations

    46

    h-index

  4. British Journal of Haematology

    BJH · 66 publications · 3.1K citations

    35

    h-index

  5. Biology of Blood and Marrow Transplantation

    TCT · 61 publications · 2.8K citations

    33

    h-index

1–5